Ariceum Therapeutics
Anika Jäkel has had a diverse work experience in the biotechnology and research fields. Anika is currently working at Ariceum Therapeutics as a Senior Director, starting in December 2022. Prior to this, they worked at Glycotope GmbH, where they held the role of Director from April 2018 to November 2022, and before that, they were a Scientist from January 2016 to March 2018. Anika also has experience at the Robert Koch Institute, where they worked as a Postdoc from November 2011 to December 2015, and as a PhD Student from August 2007 to October 2011.
Anika Jäkel has a Diplom degree in Biology from Humboldt-Universität zu Berlin, which they obtained between the years 2002 and 2007.
This person is not in any teams
This person is not in any offices
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.